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Abstract
Background: ETV6/RUNX1 (E/R) (also known as TEL/AML1) is the most frequent gene fusion in childhood acute lymphoblastic
leukemia (ALL) and also most likely the crucial factor for disease initiation; its role in leukemia propagation and
maintenance, however, remains largely elusive. To address this issue we performed a shRNA-mediated knock-down (KD) of
the E/R fusion gene and investigated the ensuing consequences on genome-wide gene expression patterns and deducible
regulatory functions in two E/R-positive leukemic cell lines.
Findings: Microarray analyses identified 777 genes whose expression was substantially altered. Although
approximately equal proportions were either up- (KD-UP) or down-regulated (KD-DOWN), the effects on biological
processes and pathways differed considerably. The E/R KD-UP set was significantly enriched for genes included in the
‘‘cell activation’’, ‘‘immune response’’, ‘‘apoptosis’’, ‘‘signal transduction’’ and ‘‘development and differentiation’’
categories, whereas in the E/R KD-DOWN set only the ‘‘PI3K/AKT/mTOR signaling’’ and ‘‘hematopoietic stem cells’’
categories became evident. Comparable expression signatures obtained from primary E/R-positive ALL samples
underline the relevance of these pathways and molecular functions. We also validated six differentially expressed
genes representing the categories ‘‘stem cell properties’’, ‘‘B-cell differentiation’’, ‘‘immune response’’, ‘‘cell adhesion’’
and ‘‘DNA damage’’ with RT-qPCR.
Conclusion: Our analyses provide the first preliminary evidence that the continuous expression of the E/R fusion gene
interferes with key regulatory functions that shape the biology of this leukemia subtype. E/R may thus indeed constitute the
essential driving force for the propagation and maintenance of the leukemic process irrespective of potential consequences
of associated secondary changes. Finally, these findings may also provide a valuable source of potentially attractive
therapeutic targets.
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Introduction
The ETV6/RUNX1 (E/R) fusion gene (also known as TEL/
AML1) is the hallmark of one of the most common genetic
subtypes of B-cell precursor acute lymphoblastic leukemia (BCP
ALL) in children [1,2]. The fusion gene encodes a chimeric
transcription factor that comprises the N-terminal portion of
ETV6 and the almost entire RUNX1 protein and is thought to
convert RUNX1 from a transcriptional modulator to a
transcriptional repressor of RUNX1 target genes [3]. The
current multistep model implies that this gene fusion occurs
already during fetal development and constitutes the initiating -
although not sufficient - event for neoplastic transformation [4,5].
The idea that the ensuing gene product might perhaps also be
relevant for maintenance of the malignant phenotype is derived
from the results of recent experiments, which showed that RNAi-
mediated silencing of the endogenous fusion gene reduces in vitro
cell proliferation and cell survival as well as significantly impairs
the in vivo repopulation capacity of the treated cells in a
xenotransplant mouse model [6] (Fuka et al. manuscript
submitted).
Microarray technologies made it possible to define the specific
gene expression signatures of specific ALL subgroups, including
those with an E/R fusion gene [7–12]. These diagnostically and
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of a differentially expressed set of genes in a given type of
leukemia relative to other subgroups included in such analyses.
Since particular genetic subgroups can be clearly delineated and
distinguished with this approach, it seems likely that primary
underlying genetic defects, as for instance E/R, are the main
determinants of the respective gene expression signature,
although the transcriptional derangements will most likely also
be modified to a certain extent by other factors, such as
secondary genetic alterations. To investigate the specific impact
of the chimeric E/R protein on overall gene expression, we
knocked down the endogenous fusion gene in two leukemia cell
lines utilizing fusion transcript specific short hairpin RNAs
(shRNA) and compared the native and suppressed gene
expression signatures. We also compared the E/R KD signature
with that obtained from primary childhood ALL cases and
validated the expression of selected target genes that represented
various pathways or cellular functions, which were identified with
this approach.
Results and Discussion
Defining target genes of E/R knockdown
We silenced the endogenous fusion protein by lentiviral
transduction of shRNA-encoding vectors in the leukemia cell
lines REH and AT-2. Detailed information on the experimental
design is provided in the Text S1. Expression profiling was
performed in cells that were selected for viral integration and
stable fusion gene suppression, which resulted in chimeric protein
reduction of 50–80% between different experiments (Figure S1).
Differentially expressed genes were determined by microarray
analyses using three and two biological replicates from indepen-
dent knock-down (KD) experiments of the REH and AT-2 cell
lines, respectively, as well as appropriate control cells that were
transduced with a non-targeting shRNA vector. Despite the
dissimilar genetic background imposed by different secondary
changes in the two cell lines there was a significant correlation of
differential gene expression in both models (r=0.31, P,0.0001)
(Figure 1). A joint analysis identified 777 genes that were
significantly (P,0.05) and concordantly up- (KD-UP; n=403)
and down-regulated (KD-DOWN; n=374) after the knockdown
of the E/R fusion gene (Table S1). The top 50 regulated genes
are listed in Table 1, along with the log2-fold changes from the
array analysis. They include, for instance, the two direct RUNX1
targets ID2 and PTPRCAP. ID2 encodes a proposed inhibitor of
tissue-specific gene expression and PTPRCAP is a key regulator of
lymphocyte activation (Table S1) [13,14]. Consistent with the
notion that E/R acts as a constitutive repressor of RUNX1 target
genes [3], these two genes are repressed in E/R-positive
leukemias and up-regulated upon fusion gene KD. In contrast
to our findings, Wotton et al. report that RUNX1-induced
repression of ID2 is abrogated by E/R. This seemingly
controversial result might possibly be explained by a context
dependent gene regulation, since Wotton et al. used 3T3 murine
fibroblast cells in their experiments. In line with our data,
PTPRCAP transcription was found to be repressed by RUNX1-
MTG8 and -MTG16 fusion genes, two RUNX1 fusions that are
frequently found in acute myeloid leukemia [14]. Furthermore,
the regulation of two other genes that are differentially expressed
in E/R-positive ALL, also concords with our E/R KD results.
CALN1, a brain-specific member of the calmodulin superfamily, is
exclusively over-expressed [10], while MS4A1 (CD20), a regulator
of B-cell activation and proliferation, appears repressed in E/R-
positive ALL [15].
Functional annotation and pathway analysis of
differentially expressed genes in the KD model
To systematically assess the molecular functions that are
modulated by E/R, we annotated all significantly regulated genes
from the E/R KD experiments according to their regulation by
the fusion gene. For this purpose, we used the ‘‘Database for
Annotation, Visualization and Integrated Discovery’’ (DAVID)
[16] to classify gene lists into functionally related gene groups. The
raw output from DAVID, derived from the analysis of up- and
down-regulated genes (Table S2 and Table S3), was further parsed
to work out more clearly the significance levels and affiliation to
broader functional groups of annotation terms (Figure 2). First
inspection of these functional annotations revealed a large
discrepancy between E/R KD up- and down-regulated genes
(Figure 2; right and left panel, respectively). While KD-UP genes
significantly associate with various cellular functions and path-
ways, the KD-DOWN gene set, after correction for multiple
testing, yielded no significant annotation term at all (the highest
ranking term with P,0.3 was the KEGG pathway 04070:Phos-
phatidylinositol signaling system). These striking differences
indicate that despite the similar number of up- and down-
regulated genes only the KD-UP ones relate, to a high degree, to
similar functions and were therefore enriched by the DAVID
analysis. The KD-DOWN genes, on the other hand, do not cluster
into common functions and therefore not a single term was found
to be significant. Hence, the channeling of KD-UP genes to
specific pathways suggests that E/R exerts its distinct and relevant
gene de-regulation through repression of specific classes of target
genes. Conversely, the general lack of such a KD-DOWN-related
‘‘pathway-channeling’’ implies that the E/R-associated up-regu-
lation of genes might be biologically far less relevant. Alternatively,
Figure 1. Scatter plot of differential gene expression values
upon E/R KD in two cell lines. Each dot represents the mean
regulation value (log2-fold change of E/R-repressed versus control cells)
of three and two replicas, for REH and AT-2 cell lines, respectively. x-axis:
REH cell line, y-axis: AT-2 cell line. Negative values indicate a decrease
and positive values an increase in gene expression upon fusion gene
KD. Green and red dots depict concordantly and significantly
modulated genes in a joint analysis of both cell lines.
doi:10.1371/journal.pone.0026348.g001
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Entrez Gene ID Gene name Gene symbol E/R KD mean E/R KD REH E/R KD AT-2
6689 Spi-B transcription factor SPIB 2.60 1.61 3.59
931 membrane-spanning 4-domains, subfamily A, member 1 MS4A1 2.58 1.83 3.32
28755 T cell receptor alpha constant TRAC 2.28 2.64 1.92
197358 NLR family, CARD domain containing 3 NLRC3 2.13 1.59 2.67
4852 neuropeptide Y NPY 2.11 1.54 2.68
100132169 LOC100132169 LOC100132169 2.06 1.45 2.68
7124 tumor necrosis factor TNF 1.91 1.47 2.35
6696 secreted phosphoprotein 1 SPP1 1.86 1.46 2.27
28514 delta-like 1 DLL1 1.80 1.70 1.89
7168 tropomyosin 1 (alpha) TPM1 1.78 1.76 1.80
3759 potassium inwardly-rectifying channel,
subfamily J, member 2
KCNJ2 1.77 1.63 1.92
1117 chitinase 3-like 2 CHI3L2 1.76 1.54 1.97
9892 synaptosomal-associated protein, 91 kDa SNAP91 1.72 2.32 1.13
7940 leukocyte specific transcript 1 LST1 1.72 1.89 1.55
3398 inhibitor of DNA binding 2 ID2 1.70 1.01 2.39
131583 family with sequence similarity 43, member A FAM43A 1.63 0.53 2.73
140706 chromosome 20 open reading frame 160 C20orf160 1.59 0.92 2.26
971 CD72 molecule CD72 1.58 2.07 1.09
54541 DNA-damage-inducible transcript 4 DDIT4 1.56 1.14 1.98
4067 v-yes-1 Yamaguchi sarcoma viral
related oncogene homolog
LYN 1.56 0.94 2.19
5790 protein tyrosine phosphatase, receptor type,
C-associated protein
PTPRCAP 1.56 1.07 2.04
374403 TBC1 domain family, member 10C TBC1D10C 1.52 0.71 2.32
7490 Wilms tumor 1 WT1 1.50 1.74 1.25
54510 protocadherin 18 PCDH18 1.49 1.32 1.65
8519 interferon induced transmembrane protein 1 IFITM1 1.46 1.96 0.96
6275 S100 calcium binding protein A4 S100A4 1.45 1.02 1.88
9639 Rho guanine nucleotide exchange factor 10 ARHGEF10 1.44 0.27 2.62
4330 meningioma 1 MN1 1.41 0.98 1.85
2014 epithelial membrane protein 3 EMP3 1.41 0.77 2.05
10870 hematopoietic cell signal transducer HCST 1.41 0.76 2.06
51523 CXXC finger 5 CXXC5 1.41 1.93 0.88
170302 aristaless related homeobox ARX 21.42 22.38 20.46
3983 actin binding LIM protein 1 ABLIM1 21.45 21.77 21.13
54549 sidekick homolog 2 SDK2 21.48 21.17 21.79
10579 transforming, acidic coiled-coil containing protein 2 TACC2 21.50 22.60 20.40
55107 anoctamin 1 ANO1 21.52 21.93 21.10
8842 prominin 1 PROM1 21.56 21.71 21.40
57556 semaphorin 6A SEMA6A 21.56 21.55 21.58
9687 growth regulation by estrogen in breast cancer 1 GREB1 21.59 21.59 21.59
8642 dachsous 1 DCHS1 21.60 21.24 21.97
650 bone morphogenetic protein 2 BMP2 21.63 22.29 20.98
55303 GTPase, IMAP family member 4 GIMAP4 21.64 21.38 21.89
83698 calneuron 1 CALN1 21.80 21.45 22.14
147700 kinesin light chain 3 KLC3 21.81 21.93 21.68
5729 prostaglandin D2 receptor PTGDR 22.01 21.18 22.85
5175 platelet endothelial cell adhesion molecule PECAM1 22.04 21.54 22.54
9619 ATP-binding cassette, sub-family G, member 1 ABCG1 22.23 22.50 21.96
5121 Purkinje cell protein 4 PCP4 22.43 20.70 24.17
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that are mostly regulated by posttranslational modifications, as is,
for instance, the case in the phosphoinositide-3-kinase (PI3K)/
AKT/mammalian target of rapamycin (mTOR) pathway.
To test for potential direct targets of E/R, we first looked for
RUNX1 consensus motifs in the promoter regions of de-regulated
genes. Using gene set enrichment (GSEA) and overrepresentation
analysis we could not detect an enrichment of such motifs in up- or
down-regulated genes (data not shown). Second, we compiled
RUNX1 targets from two very recent ChIP-seq studies [17,18],
which were derived from the analysis of human megakaryocytes
and murine hematopoietic stem/progenitor cells. GSEA revealed
that genes with ChIP-seq hits from both data sets are significantly
up-regulated in our knockdown data. Of note, the Tijssen et al
[17] data set showed a more pronounced enrichment that could be
attributable to its origin from human tissue, as opposed to mouse
tissue in the Wilson et al. study [18] (Table S5). Focussing on the
KD-UP and KD-DOWN genes, we also found a significantly
higher percentage of genes with ChIP-seq hits in KD-UP genes
compared to the KD-DOWN genes (54.8% vs. 46.8%; P=0.026,
Fisher-Exact Test) (Table S1). These results are consistent with the
notion that E/R regulates RUNX1 target genes primarily through
repression [3].
Given their apparent biological relevance, we focused our
further analysis on the 403 KD-UP genes and their molecular
functions as well as involvement in pathways. Based on the gene-
level clustering, the top 100 annotation terms were manually
curated into 14 functional meta-groups (Figure 3). Note that the
name of the meta-groups reflects only the most prominent
annotation terms that are comprised in the respective meta-group.
A list including all terms within the 14 meta-groups is shown in
Table S2. Applying stringent statistical criteria (P,0.05), only the
meta-groups ‘‘cell activation’’, ‘‘immune response’’, ‘‘apoptosis’’,
‘‘development and differentiation’’, ‘‘GTPase regulation’’, and
‘‘protein phosphorylation and phosphate metabolism’’ were found
to contain at least one significant annotation term (Figure 3A). The
regulation of individual genes within the top six meta-groups upon
E/R KD is shown in Figure 3B. The remaining groups (‘‘cell
proliferation’’, ‘‘response to wounding’’, ‘‘nucleic acid binding’’,
‘‘DNA damage response’’, ‘‘cell adhesion and migration’’,
‘‘chemical homeostasis’’, ‘‘RNA synthesis’’ and ‘‘enzyme binding’’)
contained no nominally significant annotation term.
The DAVID pathway analysis was based on the overrepresen-
tation of ‘‘significant genes’’ in certain gene sets and pathways. To
assess the functional impact of differentially expressed genes from
the E/R KD experiments independent of a specific P-value
threshold, we performed GSEA. This analysis resulted in many
more up-regulated GO terms (147) from KD-UP than down-
regulated terms (13). Importantly, these GO terms largely mapped
to the same meta-groups identified in the DAVID analysis (Table
S4). The same discrepancy (324 vs. 49 gene sets) held true for a
large collection of .2.500 gene sets that were obtained from
experimental data (‘‘curated gene sets, C2’’ from MSigDB) (Table
S5). The conclusions from the DAVID analysis were thus
qualitatively confirmed by GSEA. Moreover, in the GSEA
analysis the ‘‘Jaatinen hematopoietic stem cell UP’’ signature -
derived from the gene expression profile of sorted cord blood
CD133 (PROM1)-positive versus CD133-negative cells - emerged
as the most significantly enriched set associated with the E/R KD-
DOWN genes. This result may be an indicator for an intriguing
new function of E/R, namely that it induces genes that are
normally expressed in cord blood-derived hematopoietic stem cells
[19]. To corroborate these findings, we supplemented our
comparison with two other gene sets that were obtained from
sorted CD34+/lineage-negative versus CD342 normal bone
marrow cells designated ‘‘Andersson-UP’’ and ‘‘Andersson-
DOWN’’ (microarray data were kindly provided by Andersson
et al. [10]). In line with the above results, the ‘‘Andersson-UP’’
gene set also scored significantly in the GSEA analysis (Table S5).
Combining the data from Jaatinen’s and Andersson’s gene sets,
CALN1, PROM1, KIT and CDK6 were the most highly up-
regulated genes and they are similarly induced by E/R. With the
exception of CALN1, whose function in the hematopoietic system is
currently not known, all other genes are considered to be
associated with hematopoietic stem or progenitor cells [20].
To the best of our knowledge, only one other group has
previously analyzed the expression patterns of primary E/R-
positive ALL cases and assigned them to GO categories [11].
Consistent with our data, they also observed a distinct association
with the categories ‘‘cell differentiation’’, ‘‘cell proliferation’’,
‘‘apoptosis’’, ‘‘cell motility’’ and ‘‘response to wounding’’.
Moreover, ectopic E/R expression in a 3T3 mouse cell line
model induced the categories ‘‘adhesion’’ and ‘‘survival’’ [13].
Genes concordantly modulated by E/R KD in leukemia
model cell lines and primary ALL
Next we investigated to which extent gene expression changes
that result from an E/R KD might also be reflected in a reciprocal
fashion in primary ALL samples. For this purpose we used
previously published data sets [8] that were generated by
comparing expression profiles from E/R-positive with E/R-
negative BCP ALL cases.
The ensuing ‘‘E/R ALL signature’’ was then compared with the
E/R KD signature. Note that from the 777 significantly regulated
KD genes only 409 (n=409; 175 KD-DOWN and 234 KD-UP)
were represented in the primary ALL arrays and passed initial
quality filters (Table S6). Taking into account the specific
regulation of these genes in primary ALL, we identified a set of
genes whose expression is inversely correlated in the KD and ALL
signatures. This set comprises 66 of the 175 KD-DOWN and 71 of
the 234 KD-UP genes and they account for approximately one
third (137/409) of the E/R signature genes present in both data
sets (Table S7). In this data set, we also found a significantly higher
percentage of genes with ChIP-seq hits in KD-UP genes compared
Entrez Gene ID Gene name Gene symbol E/R KD mean E/R KD REH E/R KD AT-2
8470 sorbin and SH3 domain containing 2 SORBS2 22.47 23.21 21.73
5142 phosphodiesterase 4D, cAMP-specific PDE4B 22.79 23.27 22.31
Depicted are genes found to be significantly de-regulated in the E/R knockdown. Columns 1–3: Gene identifiers; columns 4–6: log2-fold change values for the mean of
AT-2 and REH (column 4), REH (column 5), AT-2 (column 6).
doi:10.1371/journal.pone.0026348.t001
Table 1. Cont.
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test) (Table S7). The top 50 regulated genes of this set are listed in
Table 2. They are associated with the categories ‘‘cell activation’’
(TRIB, FYB, LYN and CD72), ‘‘immune response’’ (CXCR7,
FAIM3, CD48, CD72, FKBP5), ‘‘development and differentiation’’
(SPIB, CD72, S100A4/13, PLP2), ‘‘cellular proliferation’’ (LGALS1,
CXCR7, SOX11, E2F5, GAB1, CDKN1A, EMP3, LYN, DDIT4,
CD72 and LGALS1), ‘‘cell survival’’ (DRAM1, MDM2, GAB1,
INPP5D, FAIM3, CDKN1A, LGALS1, DDIT4, CD72), ‘‘prolifera-
tive signaling’’ (GIMAP4, RAC2, ARHGEF4, PSD4), ‘‘cell adhesion
and/or migration’’ (DCHS1, CXCR7, PCDH, ITGA4, LGALS1,
ITGB2, EMP3, S100A4, LYN) and ‘‘DNA damage response’’
(DRAM1, MDM2, CDKN1A, PSD4). The above pathways and
functions match almost perfectly with those identified in the KD
model, which underscores their specific relevance for E/R-positive
leukemia.
Two thirds (272/409) of the E/R KD signature genes that
concurred with the ALL data set were not specific for E/R-positive
ALL, but were also evident in the other subgroups. This
observation evokes two, not mutually exclusive explanations,
namely that these genes are either de-regulated in a similar fashion
in a variety of ALL subtypes or that they represent a kind of basic
but essential ‘‘BCP-ALL housekeeping gene set’’. The notion that
other initiating genetic events can elicit a similar gene de-
regulation effect as E/R is, for instance, supported by the fact that
PROM1 is also up-regulated in MLL-rearranged and high-
hyperdiploid ALL cases, thereby counterbalancing its low
expression in other ALL subtypes. Consequently, PROM1 de-
regulation was not considered as being a specific feature of E/R-
positive ALL (data not shown).
Establishing a ‘‘malignancy signature’’ from the E/R KD
model
E/R KD leads to profound phenotypic changes, which
comprise impaired cellular proliferation, survival and leukemia
reconstitution in a xenotransplant mouse model (Fuka et al.,
manuscript submitted). We therefore postulated the presence of a
potential ‘‘malignancy signature’’ in the E/R KD data, whose loss
would render the expression profile of treated cells again
comparable to those of their normal counterpart. To test this
hypothesis, we generated 10 new gene sets by comparing
microarray data from primary E/R-ALL [8] with those from 5
sorted normal bone marrow derived B-cell precursor subsets [21].
Consistent with our notion, all five GSEA comparisons revealed
that genes, which are up-regulated in E/R-ALL vs. normal B-cell
precursors are overall down-regulated after the KD and vice versa
(Table S5). Therefore, this result strongly suggests that on the gene
expression level the E/R KD renders ALL cells more similar to
their physiological B-cell precursor counterparts.
Validation of selected E/R target genes by RT-qPCR
We validated the differential expression of several selected
candidate genes contained in the KD signature, which were
previously either not associated with E/R-positive ALL (PROM1,
PECAM1, IFITM1; Figure 4A) or concordantly regulated in both
systems (SPIB, MDM2 and DDIT4; Figure 4B). These genes were
chosen because of their potential biological relevance, since they
play an important role in the context of stemness and
differentiation, adhesion and migration, immune response, DNA
damage response as well as apoptosis. Notably, their differential
expression in the context of E/R is novel. Quantification results of
these transcripts in both cell lines from independent KD
experiments concurred with those of the microarray experiments
(Figure 4).
Functions of selected E/R regulated genes and potential
implications for leukemia pathogenesis
Given that GSEA analysis of E/R KD regulated genes
highlighted gene sets that are also up-regulated in hematopoietic
stem cells, we chose PROM1 (CD133) as the most prominent and
attractive candidate from this set. PROM1 is implicated in
maintaining stem cell properties by suppressing differentiation and
has recently gained much attention as a marker of tumor-initiating
cells in a variety of human cancers [22]. The fact that E/R might
regulate the expression of this gene is new and intriguing and
provides additional arguments to the ongoing debate dealing with
the structural hierarchy of ALL and its potential replenishment
from rare leukemic stem cells [23]. In favor of this notion is a
recent observation, which indicates that primitive leukemia-
initiating cells with long-term in vitro and in vivo proliferation
capabilities are exclusively found in the CD133+CD192CD382
cell compartment [24]. However, this observation is in contrast to
the scenario proposed by le Viseur et al., which suggests that the
vast majority of ALL blasts may maintain the propensity to
reconstitute leukemia in vivo [25]. The ER-induced ‘‘stemness’’
expression signature, represented for instance by PROM1 and the
stem cell factor ligand KIT in our model, therefore supports the
later view.
The E/R-induced overexpression of stem cell markers in the
respective leukemias can either be interpreted as a residual relict of
a transformed primitive stem cell or, more likely, as the reflection
of a continuously active stem cell program [26]. Although neither
possibility excludes that the gene fusion process already occurs in a
primitive hematopoietic stem cell [27], the latter requires that
inappropriate stemness genes remain active or become perhaps
reactivated at the level of maturation in which the bulk of the
leukemic cells is arrested. This interpretation is supported by the
fact that - similar to the Andersson data - E/R-positive leukemias
cluster best with normal large pre-B II cells even after suppression
of the fusion gene (data not shown) [10,21]. It is thus tempting to
speculate that up-regulation of PROM1 may play a critical role in
E/R-positive ALL. This possibility is also relevant for our recent
finding that the E/R fusion gene is apparently required for the in
vivo propagation of the respective cells (Fuka et al. manuscript
submitted).
PECAM1 (CD31) encodes a homophilic adhesion receptor that
mediates adhesion between endothelial cells and leukocytes and
could therefore probably influence adhesion and migration of
leukemic cells across the micro-vascular endothelium in various
niches [28]. Since it is also contained in Andersson’s CD34+ stem
cell signature, we envision that its over-expression also contributes
to the stem cell properties of E/R-positive ALL.
In contrast to the up-regulation of stem cell signature genes,
genes encoding B lineage differentiation markers are frequently
Figure 2. Functional annotation clustering of differentially expressed genes upon E/R KD. Visualization of the similarity of functional
annotations that were determined by DAVID for down- (left) and up-regulated (right) genes upon E/R KD. The 100 most significant terms (ranked by
P-value) are shown for both sets of annotation terms. Significance levels of functional terms are indicated by a color code shown at the bottom of the
figure. Due to large differences in the range of P-values for the functional groups resulting from up- and down-regulated genes upon KD, a different
color-scheme was used in each panel.
doi:10.1371/journal.pone.0026348.g002
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lymphoid restricted transcription factor, is one of the genes that is
strongly suppressed by E/R. Being directly induced by paired box 5
(PAX5), the master regulator of B-lineage commitment, SPIB is a
key player in B-cell development and B-cell receptor signaling
[29]. This SPIB down-regulation could thus contribute to the
impaired B-cell differentiation in E/R-positive ALL.
The E/R-associated down-regulation of IFITM1, a transcrip-
tional target of interferon (IFN) gamma [30], fits also well into one
particular point of the current concept of childhood ALL etiology,
namely the one which suggests that certain forms of childhood
ALL may be the unfortunate consequence of an abnormal
immune response to common infections [31]. The proposed
mechanism implies that inflammatory cytokines suppress the
growth of normal hematopoietic cells, whereas they do not exert
such an effect on, for instance, E/R-expressing cells. Consequent-
ly, fusion gene carrying cells may experience a relative growth
advantage. In support of this notion it was recently shown that E/
R-expressing cells are more resistant to the anti-proliferative effects
of transforming growth factor (TGF) beta [32]. Since TGF beta
and INF gamma are both key modulators of the immune system,
one expects that the suppression of IFITM1 either concurs with or
even augments these effects in response to an interferon release
during common infections. In line with the proposed function of
TGF beta, the suppression of IFITM1 may thus additionally fuel
the expansion of an E/R-expressing leukemic clone [5].
Taking into account further mechanisms that might impair an
INF gamma associated inhibition of proliferation, it is noteworthy
that CDKN1A is induced via the tumor suppressor protein p53
pathway activation and leads to a G1 cell cycle arrest [33]. The
attenuation of the p53 activity together with the transcriptional
repression of its direct target p21, the gene product of CDKN1A,
either by E/R-mediated repression of IFITM1 or up-regulation of
the p53 inhibitor MDM2, as implied in our KD model, opens
another fascinating layer of complexity to the E/R-mediated gene
regulation process. Given that p53 acts as a gatekeeper of genome
integrity [34], p53 down-regulation by any of the above outlined
means may thus favor leukemia development. Intriguingly,
MDM2 is induced by RUNX1-RUNX1T1 and may therefore
be involved in the route of transformation in a similar fashion in
other RUNX1-associated leukemias, as for instance the E/R-
positive ones [35]. Furthermore, MDM2 may also promote
tumorigenesis via a p53 independent mechanism [36]. Such
findings are not only crucial for our understanding of leukemia
development per se, but may be particularly helpful for the
identification of especially relevant targets for tailored future
therapies.
Another E/R-down-regulated gene that is involved in the p53
pathway is DDIT4 (also known as REDD1). It is primarily induced
by stress and negatively regulates the mTOR pathway. DDIT4 is
activated by DNA damage via p53-dependent and -independent
mechanisms, but also by hypoxia or energy stress [37]. Particularly
this latter feature is interesting in the context of E/R-positive
leukemia, because the majority of affected children are anemic at
diagnosis, which seemingly grants hypoxic conditions a central
role in their pathogenesis [38]. Noteworthy, E/R-associated
DDIT4 suppression may further contribute to the observed
PI3K/AKT/mTOR pathway activation and an improved cell
survival [39]. Whether this suppression is a direct p53-related
consequence that, as recently observed in breast cancer, also leads
to hypoxia inducible factor (HIF) 1 alpha accumulation, is
currently not known [40].
Taken together, the above clues reinforce the essential role that
E/R plays in the entire process of leukemia development and
maintenance: i) It induces genes that confer stem cell properties
endowing cells with unlimited self renewal capability and
simultaneously represses genes that otherwise promote differenti-
ation; ii) it alters the DNA damage response by attenuating the p53
pathway, which in addition enables the survival and clonal
expansion of cells with accumulating secondary genetic changes;
iii) it triggers proliferation and cellular growth via PI3K/AKT/
mTOR pathway activation, which in turn adapts extracellular
signaling as well as stress and hypoxia response accordingly; iv) it
also attenuates the response to inflammatory signals. All these
features, sustaining proliferative signaling, evading growth sup-
pression, resisting cell death, and induced genome instability, are
typical and well established hallmarks of cancer in general [41].
Based on the analyses of our KD model, we have established a
functional map of the consequences of E/R expression in an
endogenous background. The modulation of various specific and
more general key processes that are pivotal for leukemia
pathogenesis was thus highlighted. These processes include
‘‘development and differentiation’’, ‘‘apoptosis’’, ‘‘adhesion and
migration’’ as well as ‘‘DNA damage response’’. Finally, these data
provide also a valuable source of interesting targets and pathways
whose functional validation will provide further insights into the
biology of E/R-positive leukemia and possibly also promote the
identification of novel targets for treatment.
Materials and Methods
Quantitative RT-PCR (RT-qPCR)
Total RNA was isolated from biological replicates of E/R-
silenced REH (n=3) and AT-2 (n=3) cells obtained from
independent KD experiments by Trizol reagent (Life Technolo-
gies, Carlsbad, CA). cDNA was synthesized by SuperScript II
Reverse Transcriptase according to the manufacturer’s recom-
mendations (Invitrogen, Carlsbad, CA). Transcripts were quanti-
fied by TaqMan RT-qPCR using the ABI Prism 7900 Detection
System (Applied Biosystems, Foster City, CA). The following











CATCCAAGGTGGGATCGT-39 and IFITM1 59-GGCTTCA-
TAGCATTCGCCTA-39,5 9-ATGAGGATGCCCAGAATCAG-
39,5 9 TCCACCGCCAAGTGCCTGAA-39. GUSB was detected
Figure 3. Meta-groups of functional annotations for up-regulated genes upon E/R KD. Meta-groups were curated based on gene-
clustering of annotation terms. A: Top 100 annotation terms from KD-UP genes, their P-values and their affiliation to meta-groups. Similarity of the
meta-groups was based on the number of shared genes. For distance calculations between the meta-groups genes from all contributing terms were
taken together. B: Change in expression of individual genes in meta-groups that contain significant annotation terms. The color code at the bottom
of the figure indicates the extent of log2-fold changes in gene expression.
doi:10.1371/journal.pone.0026348.g003
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Entrez gene ID Gene name Gene symbol E/R KD mean E/R+ vs. E/R2 ALL
6689 Spi-B transcription factor SPIB 2.60 21.83
28755 T cell receptor alpha constant TRAC 2.28 21.03
971 CD72 molecule CD72 1.58 20.80
54541 DNA-damage-inducible transcript 4 DDIT4 1.56 21.37
4067 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog LYN 1.56 21.26
6275 S100 calcium binding protein A4 S100A4 1.45 21.80
2014 epithelial membrane protein 3 EMP3 1.41 20.88
3689 integrin, beta 2 ITGB2 1.31 21.35
23550 pleckstrin and Sec7 domain containing 4 PSD4 1.30 20.35
26112 coiled-coil domain containing 69 CCDC69 1.25 21.50
3956 lectin, galactoside-binding, soluble, 1 LGALS1 1.11 22.00
64777 required for meiotic nuclear division 5 homolog B RMND5B 1.06 20.21
1026 cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 1.05 20.56
51063 calcium homeostasis modulator 2 CALHM2 0.99 21.09
9404 leupaxin LPXN 0.95 21.55
5355 proteolipid protein 2 PLP2 0.90 21.47
2289 FK506 binding protein 5 FKBP5 0.89 20.95
962 CD48 molecule CD48 0.89 20.81
55501 carbohydrate (chondroitin 4) sulfotransferase 12 CHST12 0.86 20.72
9679 family with sequence similarity 53, member B FAM53B 0.86 21.07
10437 interferon, gamma-inducible protein 30 IFI30 0.85 20.55
3676 integrin, alpha 4 ITGA4 0.83 21.08
5880 ras-related C3 botulinum toxin substrate 2 RAC2 0.82 20.53
6284 S100 calcium binding protein A13 S100A13 0.81 20.75
272 adenosine monophosphate deaminase 3 AMPD3 0.80 20.34
9331 beta 1,4- galactosyltransferase, polypeptide 6 B4GALT6 20.72 1.68
10656 KH domain containing, RNA binding, signal
transduction associated 3
KHDRBS3 20.75 2.04
5101 protocadherin 9 PCDH9 20.77 1.68
1875 E2F transcription factor 5 E2F5 20.81 0.68
50649 Rho guanine nucleotide exchange factor 4 ARHGEF4 20.81 3.32
9214 Fas apoptotic inhibitory molecule 3 FAIM3 20.84 0.74
6664 SRY (sex determining region Y)-box 11 SOX11 20.84 2.39
10402 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 ST3GAL6 20.87 0.74
26011 odz, odd Oz/ten-m homolog 4 ODZ4 20.88 0.49
57007 chemokine (C-X-C motif) receptor 7 CXCR7 20.91 1.19
2533 FYN binding protein FYB 20.91 2.48
8349 histone cluster 2, H2be HIST2H2BE 20.91 0.94
5095 propionyl CoA carboxylase, alpha polypeptide PCCA 20.94 1.38
3635 inositol polyphosphate-5-phosphatase INPP5D 21.03 0.37
2549 GRB2 associated binding protein 1 GAB1 21.05 1.23
54847 SID1 transmembrane family, member 1 SIDT1 21.06 0.92
10221 tribbles homolog 1 TRIB1 21.09 1.11
4193 mouse double minute 2 MDM2 21.11 0.56
55332 DNA-damage regulated autophagy modulator 1 DRAM1 21.16 2.28
950 scavenger receptor class B, member 2 SCARB2 21.21 0.46
57556 semaphorin 6A SEMA6A 21.56 1.95
8642 dachsous 1 DCHS1 21.60 1.18
650 bone morphogenetic protein 2 BMP2 21.63 1.53
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used as endogenous reference. Shown are cycle threshold D(CT)
values.
Gene expression analysis by microarray technology
Gene expression changes upon knockdown of E/R were
followed on Affymetrix HG-U133-PLUS2 arrays (Affymetrix,
Inc., Santa Clara, CA). cRNA target synthesis and GeneChipH
processing were performed in the Gene Expression Profiling Unit
of the Medical University Innsbruck according to standard
protocols (Affymetrix, Inc., Santa Clara, CA). Microarray data
were performed in compliance to MIAME guidelines and
submitted to GEO - accession number GSE29639. All further
analyses were performed in R statistical environment using
Bioconductor packages [43].
Affymetrix CEL files were preprocessed as described previously
[44], yielding a final number of 9.498 probesets that were used for
all further analyses.
Differentially expressed genes were determined using a
moderated t-test in the R package ‘‘limma’’ [45]. All P-values
were corrected for multiple testing using the ‘‘Benjamini-Hoch-
berg’’ correction method. Significantly changing genes in the E/R
KD vs. control experiments were determined by calculating ratios
for each gene between the two conditions for each experiment
separately, thus yielding five biological replicates of relative
expression for each gene (REH, n=3; AT2, n=2). Then, for
each gene, significance was determined using a weighted one-
sample t-test against the null hypothesis of no expression change
(m=0).
For the re-analysis of primary ALL data set from Ross et al. [8],
CEL files were downloaded from the St. Jude’s data server and
microarray data was pre-processed as described previously [44],
generating a data set of 12.068 genes. In this data set E/R-positive
vs. E/R-negative BCP ALL samples were compared and yielded
1.980 differentially regulated genes (P,0.05, moderated t-test),
1.008 of which were under- and 972 over-expressed in E/R-
positive ALL. Combining the data sets from Ross [8] and the KD
experiments a total of 5.119 genes were represented on both
platforms independent of their regulation and passed initial quality
filters (Table S6). This gene set was then used to look for genes that
are regulated by E/R in KD experiments and primary ALL.
To test for differences in malignant vs. non-malignant cells, we
analyzed E/R-positive ALL from the Ross data set [8] together
with microarray data from five normal bone marrow B-cell
precursor subsets [21] (http://franklin.et.tudelft.nl/).
Functional annotation
The ‘‘Database for Annotation, Visualization and Integrated
Discovery’’ (DAVID) was used to annotate the 403 up- and 374
down-regulated genes from the joint analysis of the E/R
Entrez gene ID Gene name Gene symbol E/R KD mean E/R+ vs. E/R2 ALL
55303 GTPase, IMAP family member 4 GIMAP4 21.64 1.14
5142 phosphodiesterase 4D, cAMP-specific PDE4B 22.79 0.78
Depicted are genes found to be significantly and concordantly de-regulated by E/R in KD experiments and E/R-positive vs. E/R-negative primary BCP ALL from Ross et al.




Figure 4. Validation of selected differentially expressed genes from the KD experiments by RT-qPCR. Quantification of transcripts of
differentially expressed genes. A: Concordantly de-regulated by E/R in the KD and primary leukemias. B: Only regulated in the KD experiments. Boxes
cover the median and the interquartile range (25–75th percentiles) and whiskers the minimum and maximum values. *, P#0.05; **, P#0.01;
***, P#0.001 (paired t-test).
doi:10.1371/journal.pone.0026348.g004
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Tool’’ in the online version of DAVID was run (http://david.abcc.
ncifcrf.gov/) using the default parameters and focusing on the
categories Gene Ontology-Molecular Function, Gene-Ontology-
Biological Process and KEGG/Biocarta Pathways. All annotation
terms that met the inclusion criteria were downloaded as
‘‘Functional Charts’’.
Hierarchical clustering of annotation terms
For further analysis and visualization of the similarity among
annotation terms, the functional charts were first sorted by their P-
value (corrected for multiple testing by the Benjamini-Hochberg
method) and then, to determine the relationships of the top 100
annotation terms, similarity between all terms was measured by
the number of their shared genes (gDist as described in Kauer et
al. 2009) [44]. The matrix of pair wise gDist values (as
dissimilarities: 1-gDist) for the 100 most significant terms was
used as input for hierarchical clustering using the R function
‘‘hclust’’ in combination with the ‘‘average linkage’’ algorithm.
Finally, the similarity among the annotation terms was visualized
as dendrogram in combination with a heatmap indicating
significance levels of the clustered terms. Names of meta-groups
were chosen or modified from upstream gene ontology terms
(http://www.geneontology.org/).
Gene set enrichment
To define functional categories of de-regulated genes indepen-
dent of a P-value cutoff for ‘‘significant genes’’, we performed gene
set enrichment analysis (GSEA) using the ‘‘pGSEA’’ package in
the Bioconductor/R environment [46–48]. Gene-wise log2
expression ratios (logFC) of knockdown versus control for the cell
lines REH and AT-2, and for the mean of their logFCs, were used
as input for pGSEA. Gene sets were downloaded from the
MSigDB v3.0 (http://www.broad.mit.edu/gsea/msigdb/ Cam-
bridge, USA). We tested two different gene set collections available
from MSigDB: curated gene sets from canonical pathways and
experimental data (C2) and GO terms (C5). To validate the
enrichment on genes involved in hematopoietic stem cells, we
added two more gene sets to the C2 group: genes up- and down-
regulated in the Andersson et al. 2005 data set (CD34+/lineage
negative vs. CD342 hematopoietic cells) [10].
To test whether E/R knockdown renders the gene expression of
ALL cells more similar to non-malignant cells, we added new gene
sets: For each of the five comparisons of E/R ALL vs. normal B-
cell precursor subsets we defined significantly (P,0.01,
logFC.1.5) up- and down-regulated genes, resulting in 10 gene
sets. The results for all gene sets can be found in Table S5.
To test for enrichment of putative direct RUNX1 binding
targets, RUNX1 ChIP-seq data was downloaded from two
sources: Tijssen et al. [17]; Wilson et al. [18].
Deposition of microarrays
Microarray data are available online at GEO (www.ncbi.nlm.
nih.gov/geo/, accession number GSE29639).
Supporting Information
Text S1 Materials and methods.
(DOC)
Figure S1 shRNA-mediated silencing of E/R leads to
chimeric protein depletion. The E/R-positive leukemia cell
lines REH and AT-2 were transduced by lentiviral constructs
encoding eitherthe E/R specificshRNAG1 (G1) or a non-targeting
shRNA (control). Protein levels of E/R (A) and RUNX1 (B) were
detected by immunoblotting using anti-ETV6 and anti-RUNX1
antibodies, respectively. GAPDH was used to ensure equal loading.
Numbers between bands represent the ratio between tested proteins
and GAPDH quantification. A vertical line has been inserted to
indicate where a gel lane was cut. These gels came from identical
experiments. Shown are results from one of at least three
independent E/R knockdown experiments per cell line.
(TIF)
Table S1 Genes found to be significantly de-regulated
on Affymetrix HGU-133-PLUS2 arrays from E/R KD
experiments. Columns 1–3: Gene identifiers; columns 4–6:
log2-fold change values (mean of AT-2 and REH) (column 4),
REH (column 5), AT-2 (column 6); column 7: P-value for the
mean log2-fold changes of the E/R KD (from column 4) corrected
by the Benjamini-Hochberg method; column 8: ChIP-seq hits
from Tijssen et al. [17]; column 9: ChIP-seq hits from Wilson et al.
[18].
(XLS)
Table S2 Output from the DAVID analysis (version 6.7)
for significantly up-regulated genes upon E/R KD. The
Categories ‘‘GO-Molecular Function’’, ‘‘GO-Biological Process’’
and ‘‘Pathways’’ were selected for testing. Description of columns:
‘‘Category’’ – categories from DAVID; ‘‘Term’’ – specific terms
within DAVID-categories; ‘‘Meta-group’’ – affiliation of ‘‘Term’’
into a meta-group, ‘‘Gene symbols’’ – genes from the tested gene
list involved in ‘‘Term’’; ‘‘Fold enrichment’’ – enrichment of genes
involved in ‘‘Term’’ over random expectation; ‘‘P-value’’ – P-
values for enrichment calculated by the EASE method used in
DAVID; ‘‘Benjamini’’ – P-values corrected for multiple testing by




Table S3 Output from the DAVID analysis (version 6.7)
for significantly down-regulated genes upon E/R KD.
Column descriptions as for Table S2.
(XLS)
Table S4 Results from the GSEA analysis for GO gene
sets (MSigDB: C5). Column 1: name of the MSIGDb gene set;
columns 2–4: z-scores of from the pGSEA algorithm; columns 5–
7: P-values from the pGSEA algorithm; column 8: genes involved
in gene set; columns 9–12: descriptions of MSigDB gene set from
MSigDB.
(XLS)
Table S5 Results from the GSEA analysis for ‘‘curated
gene sets’’ from MSigDB (C2). Column descriptions as for
Table S4.
(XLS)
Table S6 All 5.119 probe sets that passed quality filters
that were present on both, the HGU-133-PLUS2 arrays
from our E/R KD experiments and E/R-positive vs. E/
R-negative primary BCP ALL (from Ross et al. [8]; HGU-
133-A arrays). Columns 1, 2: Gene symbol (column 1) and
Probe set (column 2) identifiers; columns 3, 4: log2-fold change
values (column 3) and P-values (column 4) for the mean value of
the E/R KD; columns 5, 6: log2-fold change values (column 5)
and P-values (column 6) for E/R-positive vs. E/R-negative primary
BCP ALL. Mean log2-fold change and P-values were calculated as
described in the M&M section.
(XLS)
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from the E/R KD signature and E/R-positive vs. E/R-
negative primary BCP ALL (from Ross et al. [8]). The
subset of 137 genes from Table S4 with P,0.05 for both, the mean
from E/R knockdown vs. control and E/R-positive vs. E/R-negative
primary BCP ALL. Columns 1, 2: gene identifiers; columns 3, 4:
log2-fold change values (column 3) and P-values (column 4) for the
mean value of the E/R KD; columns 5, 6: log2-fold change values
(column 5) and P-values (column 6) for E/R-positive vs. E/R-
negativeprimaryBCP ALL;column7:ChIP-seq hits fromTijssen et
al. [17]; column 8: ChIP-seq hits from Wilson et al. [18].
(XLS)
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